Innocare Pharma

Innocare Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

Company Details

Employees
123
Founded
-
Address
Building 8, No. 8 Life Science Park Road, Zhongguancun Life Science Park, Changping District,beijing,china
Phone
+86 10 66609999
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Beijing
Looking for a particular Innocare Pharma employee's phone or email?

Innocare Pharma Questions

News

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - GlobeNewswire

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis GlobeNewswire

InnoCare Releases 2025 Interim Results and Business Highlights - Yahoo Finance

InnoCare Releases 2025 Interim Results and Business Highlights Yahoo Finance

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors - OncLive

Zurletrectinib Receives Priority Review from NMPA for NTRK Gene Fusion+ Advanced Solid Tumors OncLive

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02 - Business Wire

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02 Business Wire

BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis - NeurologyLive

BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis NeurologyLive

InnoCare Pharma secures a licensing agreement exceeding $2 billion, achieving another breakthrough for its core product in overseas markets. - 富途牛牛

InnoCare Pharma secures a licensing agreement exceeding $2 billion, achieving another breakthrough for its core product in overseas markets. 富途牛牛

InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China - Clinical Trials Arena

InnoCare Pharma receives approval for CLL/SLL combination therapy trial in China Clinical Trials Arena

Lymphoma Treatment Market Size to Hit USD 16.62 Billion by 2034 - Precedence Research

Lymphoma Treatment Market Size to Hit USD 16.62 Billion by 2034 Precedence Research

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore - GlobeNewswire

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore GlobeNewswire

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma - OncLive

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma OncLive

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis - Biogen

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis Biogen

Biopharma startup InnoCare launches new cancer drug - China Daily - Global Edition

Biopharma startup InnoCare launches new cancer drug China Daily - Global Edition

InnoCare and ArriVent Announce Clinical Development Collaboration - GlobeNewswire

InnoCare and ArriVent Announce Clinical Development Collaboration GlobeNewswire

Top Innocare Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant